Kraig Biocraft Laboratories, Inc. (KBLB)
OTCMKTS · Delayed Price · Currency is USD
0.147
-0.003 (-2.00%)
Apr 29, 2026, 1:05 PM EST

KBLB Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
3.212.912.381.942.56
Upgrade
Research & Development
0.170.160.240.180.2
Upgrade
Operating Expenses
3.373.072.612.122.76
Upgrade
Operating Income
-3.37-3.07-2.61-2.12-2.76
Upgrade
Interest Expense
-0.57-0.53-0.48-1.72-5.36
Upgrade
Interest & Investment Income
0.010.070.11--
Upgrade
EBT Excluding Unusual Items
-3.93-3.53-2.99-3.84-8.12
Upgrade
Gain (Loss) on Sale of Investments
0.310.130.060-0.01
Upgrade
Asset Writedown
---0.1--
Upgrade
Other Unusual Items
----0.09
Upgrade
Pretax Income
-3.62-3.4-3.03-3.84-8.05
Upgrade
Net Income
-3.62-3.4-3.03-3.84-8.05
Upgrade
Net Income to Common
-3.62-3.4-3.03-3.84-8.05
Upgrade
Shares Outstanding (Basic)
1,0591,0381,033974878
Upgrade
Shares Outstanding (Diluted)
1,0591,0381,033974878
Upgrade
Shares Change (YoY)
2.03%0.51%6.04%11.02%3.41%
Upgrade
EPS (Basic)
-0.00-0.00-0.00-0.00-0.01
Upgrade
EPS (Diluted)
-0.00-0.00-0.00-0.00-0.01
Upgrade
Free Cash Flow
-1.79-1.84-1.25-1.89-1.9
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00
Upgrade
EBITDA
-3.35-3.05-2.59-2.09-2.73
Upgrade
D&A For EBITDA
0.030.030.030.030.03
Upgrade
EBIT
-3.37-3.07-2.61-2.12-2.76
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.